- Home
- CRVS vs CRNT Comparison
CRVS vs CRNT Comparison
Compare CRVS & CRNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- CRNT
- Stock Information
- Founded
- CRVS 2014
- CRNT 1996
- Country
- CRVS United States
- CRNT Israel
- Employees
- CRVS N/A
- CRNT N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- CRNT Radio And Television Broadcasting And Communications Equipment
- Sector
- CRVS Health Care
- CRNT Technology
- Exchange
- CRVS Nasdaq
- CRNT Nasdaq
- Market Cap
- CRVS 257.0M
- CRNT N/A
- IPO Year
- CRVS 2016
- CRNT 2000
- Fundamental
- Price
- CRVS $3.21
- CRNT $2.44
- Analyst Decision
- CRVS Strong Buy
- CRNT Strong Buy
- Analyst Count
- CRVS 5
- CRNT 5
- Target Price
- CRVS $12.63
- CRNT $6.15
- AVG Volume (30 Days)
- CRVS 704.3K
- CRNT 1.0M
- Earning Date
- CRVS 05-05-2025
- CRNT 05-06-2025
- Dividend Yield
- CRVS N/A
- CRNT N/A
- EPS Growth
- CRVS N/A
- CRNT 285.71
- EPS
- CRVS N/A
- CRNT 0.27
- Revenue
- CRVS N/A
- CRNT $394,190,000.00
- Revenue This Year
- CRVS N/A
- CRNT $3.36
- Revenue Next Year
- CRVS N/A
- CRNT $7.39
- P/E Ratio
- CRVS N/A
- CRNT $8.74
- Revenue Growth
- CRVS N/A
- CRNT 13.54
- 52 Week Low
- CRVS $1.30
- CRNT $2.25
- 52 Week High
- CRVS $10.00
- CRNT $5.73
- Technical
- Relative Strength Index (RSI)
- CRVS 29.29
- CRNT 36.31
- Support Level
- CRVS $3.06
- CRNT $2.29
- Resistance Level
- CRVS $3.45
- CRNT $2.65
- Average True Range (ATR)
- CRVS 0.37
- CRNT 0.12
- MACD
- CRVS -0.10
- CRNT 0.04
- Stochastic Oscillator
- CRVS 8.77
- CRNT 35.19
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).